<p>史密斯与内夫公司（NYSE:SNN - 获取免费报告）的股票在周二交易前跳空上涨。该股票此前收于 26.28 美元，但开盘价为 27.82 美元。史密斯与内夫的股票最后交易价格为 27.90 美元，成交量为 248,651 股。</p>
<p>获取 <strong>史密斯与内夫</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>圣诞反弹提前到来，这些股票受益</li>
</ul>
<p>多家券商对 SNN 进行了评估。德意志银行将史密斯与内夫的评级从 “买入” 下调至 “持有”，该报告于 11 月 1 日星期五发布。StockNews.com 将史密斯与内夫的评级从 “强力买入” 下调至 “买入”，该研究报告于 11 月 12 日星期二发布。最后，贝伦贝格银行在 11 月 6 日星期三的报告中将史密斯与内夫的评级从 “买入” 下调至 “持有”。</p>
<p><strong>查看我们对 SNN 的最新分析</strong></p>
<h2>史密斯与内夫股票表现</h2>
<ul>
<li>外科中心、医疗科技股票因手术需求积压而上涨</li>
</ul>
<p>该公司的债务与股本比率为 0.63，速动比率为 1.11，流动比率为 2.51。公司的 50 日移动平均价格为 25.06 美元，200 日移动平均价格为 27.23 美元。公司的市值为 122.7 亿美元，市盈率为 12.97，市盈增长比率为 1.26，贝塔值为 0.84。</p>
<h2>机构投资者对史密斯与内夫的看法</h2>
<p>几家大型投资者最近增加或减少了对该公司的持股。国际资产投资管理公司在第三季度购买了价值约 792,000 美元的史密斯与内夫新股份。查尔斯·施瓦布投资管理公司在第三季度将其在史密斯与内夫的持股增加了 29.3%。查尔斯·施瓦布投资管理公司现在拥有 27,199 股该医疗设备提供商的股票，价值 847,000 美元，此前在上个季度又购买了 6,164 股。斯蒂费尔金融公司在第三季度购买了价值 1,258,000 美元的史密斯与内夫新股份。马弗里克资本有限公司在第三季度购买了价值约 2,086,000 美元的史密斯与内夫新股份。最后，蓝信托公司在第四季度将其在史密斯与内夫的持股增加了 26.0%。蓝信托公司现在拥有 5,871 股该医疗设备提供商的股票，价值 144,000 美元，此前在此期间又购买了 1,213 股。对冲基金和其他机构投资者持有该公司 25.64% 的股份。</p>
<h2>关于史密斯与内夫</h2>
<p>（获取免费报告）</p>
<ul>
<li>三家医疗保健分红支付者，价格增长显著</li>
</ul>
<p>史密斯与内夫公司从事医疗设备的开发、制造、营销和销售。它通过以下几个部门运营：骨科、运动医学和耳鼻喉科，以及先进的伤口管理。骨科和运动医学及耳鼻喉科部门包括以下业务：膝关节植入物、髋关节植入物、其他重建、创伤、运动医学关节修复、关节镜辅助技术和耳鼻喉科。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过史密斯与内夫</li>
<li>在衰退中乘风破浪的分红之王</li>
<li>二月的三大股票升级：投资者需要知道的事项</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>2 只避险股票，免受进口关税影响</li>
<li>天然气价格持续上涨，这些股票将受益</li>
<li>Nebius Group：投资者的战略切入点？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在史密斯与内夫吗？</h2>
<p>在你考虑投资史密斯与内夫之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而史密斯与内夫并不在名单上。</p>
<p>虽然史密斯与内夫目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>史密斯与内甫（NYSE:SNN）股票在周二交易前从 26.28 美元跳空上涨至 27.82 美元，最终收于 27.90 美元，成交量为 248,651 股。最近的分析师评级显示，德意志银行等机构将其评级从 “买入” 下调至 “持有”。该公司的市值为 122.7 亿美元，市盈率为 12.97，债务与股本比率为 0.63。机构投资者持有该股票的 25.64%，并有显著的近期购买。尽管价格走势积极，分析师建议考虑其他股票进行投资</p>

<p>Shares of Smith &amp; Nephew plc (NYSE:SNN - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $26.28, but opened at $27.82. Smith &amp; Nephew shares last traded at $27.90, with a volume of 248,651 shares changing hands.</p>
<div class="lb-trans"><p>史密斯与内夫公司（NYSE:SNN - 获取免费报告）的股票在周二交易前跳空上涨。该股票此前收于 26.28 美元，但开盘价为 27.82 美元。史密斯与内夫的股票最后交易价格为 27.90 美元，成交量为 248,651 股。</p>
</div><p>Get <strong>Smith &amp; Nephew</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>史密斯与内夫</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Santa Rally comes early for these stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>圣诞反弹提前到来，这些股票受益</li>
</ul>
</div><p>A number of brokerages have weighed in on SNN. Deutsche Bank Aktiengesellschaft lowered Smith &amp; Nephew from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, November 1st. StockNews.com downgraded Smith &amp; Nephew from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday, November 12th. Finally, Berenberg Bank lowered Smith &amp; Nephew from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, November 6th.</p>
<div class="lb-trans"><p>多家券商对 SNN 进行了评估。德意志银行将史密斯与内夫的评级从 “买入” 下调至 “持有”，该报告于 11 月 1 日星期五发布。StockNews.com 将史密斯与内夫的评级从 “强力买入” 下调至 “买入”，该研究报告于 11 月 12 日星期二发布。最后，贝伦贝格银行在 11 月 6 日星期三的报告中将史密斯与内夫的评级从 “买入” 下调至 “持有”。</p>
</div><p><strong>View Our Latest Analysis on SNN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 SNN 的最新分析</strong></p>
</div><h2>Smith &amp; Nephew Stock Performance</h2>
<div class="lb-trans"><h2>史密斯与内夫股票表现</h2>
</div><ul>
<li>Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand</li>
</ul>
<div class="lb-trans"><ul>
<li>外科中心、医疗科技股票因手术需求积压而上涨</li>
</ul>
</div><p>The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company's 50 day moving average price is $25.06 and its 200-day moving average price is $27.23. The company has a market cap of $12.27 billion, a PE ratio of 12.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.84.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.63，速动比率为 1.11，流动比率为 2.51。公司的 50 日移动平均价格为 25.06 美元，200 日移动平均价格为 27.23 美元。公司的市值为 122.7 亿美元，市盈率为 12.97，市盈增长比率为 1.26，贝塔值为 0.84。</p>
</div><h2>Institutional Investors Weigh In On Smith &amp; Nephew</h2>
<div class="lb-trans"><h2>机构投资者对史密斯与内夫的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new stake in shares of Smith &amp; Nephew during the 3rd quarter valued at approximately $792,000. Charles Schwab Investment Management Inc. grew its position in shares of Smith &amp; Nephew by 29.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider's stock valued at $847,000 after purchasing an additional 6,164 shares in the last quarter. Stifel Financial Corp bought a new stake in shares of Smith &amp; Nephew during the 3rd quarter valued at $1,258,000. Maverick Capital Ltd. purchased a new stake in Smith &amp; Nephew during the 3rd quarter worth about $2,086,000. Finally, Blue Trust Inc. boosted its stake in Smith &amp; Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock worth $144,000 after purchasing an additional 1,213 shares during the period. Hedge funds and other institutional investors own 25.64% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对该公司的持股。国际资产投资管理公司在第三季度购买了价值约 792,000 美元的史密斯与内夫新股份。查尔斯·施瓦布投资管理公司在第三季度将其在史密斯与内夫的持股增加了 29.3%。查尔斯·施瓦布投资管理公司现在拥有 27,199 股该医疗设备提供商的股票，价值 847,000 美元，此前在上个季度又购买了 6,164 股。斯蒂费尔金融公司在第三季度购买了价值 1,258,000 美元的史密斯与内夫新股份。马弗里克资本有限公司在第三季度购买了价值约 2,086,000 美元的史密斯与内夫新股份。最后，蓝信托公司在第四季度将其在史密斯与内夫的持股增加了 26.0%。蓝信托公司现在拥有 5,871 股该医疗设备提供商的股票，价值 144,000 美元，此前在此期间又购买了 1,213 股。对冲基金和其他机构投资者持有该公司 25.64% 的股份。</p>
</div><h2>About Smith &amp; Nephew</h2>
<div class="lb-trans"><h2>关于史密斯与内夫</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>3 Healthcare Dividend Payers With Big Price Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗保健分红支付者，价格增长显著</li>
</ul>
</div><p>Smith &amp; Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.</p>
<div class="lb-trans"><p>史密斯与内夫公司从事医疗设备的开发、制造、营销和销售。它通过以下几个部门运营：骨科、运动医学和耳鼻喉科，以及先进的伤口管理。骨科和运动医学及耳鼻喉科部门包括以下业务：膝关节植入物、髋关节植入物、其他重建、创伤、运动医学关节修复、关节镜辅助技术和耳鼻喉科。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Smith &amp; Nephew</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>February’s Top 3 Stock Upgrades: What Investors Need to Know</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>2 Safe-Haven Stocks Shielded From Import Tariffs</li>
<li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li>
<li>Nebius Group: A Strategic Entry Point for Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过史密斯与内夫</li>
<li>在衰退中乘风破浪的分红之王</li>
<li>二月的三大股票升级：投资者需要知道的事项</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>2 只避险股票，免受进口关税影响</li>
<li>天然气价格持续上涨，这些股票将受益</li>
<li>Nebius Group：投资者的战略切入点？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Smith &amp; Nephew Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在史密斯与内夫吗？</h2>
</div><p>Before you consider Smith &amp; Nephew, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资史密斯与内夫之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith &amp; Nephew wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而史密斯与内夫并不在名单上。</p>
</div><p>While Smith &amp; Nephew currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然史密斯与内夫目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Smith & Nephew (NYSE:SNN) 股价跳空上涨 - 以下是原因